There is increasing impetus to use pharmaceutical interventions, ie, ranibizumab or bevacizumab, for the treatment of particular macular diseases. This paper describes the evidence and decision-making of the National List of Essential Medicines Committee that recently announced the inclusion of bevacizumab for the treatment of macular diseases in its pharmaceutical benefit package. The findings of a systematic review and meta-analysis in this paper indicate that the intravitreal administration of bevacizumab is superior to nonpharmaceutical treatments for age-related macular degeneration (AMD) and diabetic macular edema (DME), but inconclusive for retinal vein occlusion, given the limited evidence. The study also failed to distinguish among the differences in terms of visual acuity improvement, reduction of central macular thickness, and response to treatment between AMD and DME patients treated with bevacizumab and those treated with ranibizumab. Although bevacizumab was not licensed for AMD and DME, the committee decided to include bevacizumab in the National List of Essential Medicines. It is expected that many patients who are in need of treatment but who are unable to afford the expensive alternative drug, ranibizumab, will be able to receive this effective treatment instead and be prevented from suffering irreversible loss of vision. At the same time, this policy will help generate evidence about the real-life effectiveness and safety profiles of the drug for future policy development in Thailand and other settings.
The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package 
Introduction
Universal health-care coverage has been available in Thailand since 2003, meaning that the Royal Thai Government ensures the universal access of essential health-care services for the country's 67 million people. 1 This is achieved via the National List of Essential Medicines (NLEM), a national drug list that is used as a reference for the pharmaceutical benefit package for all public health insurance schemes. 2 All patients who meet the medical criteria are entitled to receive the free medications listed in the NLEM. Continuously developed by a subcommittee with extensive support from clinical experts and public research institutes, this list currently covers more than 800 drug formularies. 3 Since its establishment in 2006, the Health Intervention and Technology Assessment Program (HITAP), which is a national health-technology assessment agency, has played a part in the development of the NLEM. 4 In 2011, the subcommittee requested that HITAP investigate the clinical efficacy/effectiveness and safety of bevacizumab and ranibizumab compared with other nonpharmaceutical interventions for the treatment of age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The request was based on the fact that there were no medications in the NLEM available for the treatment of these diseases, even though several empirical studies indicated significant benefits of pharmaceutical interventions. [5] [6] [7] [8] [9] [10] [11] This resulted in the inaccessibility of the drugs for patients who cannot afford these proven medicines. Therefore, the aim of this study is to inform the NLEM subcommittee in order to further refine the NLEM via the analysis of the study's results and the policy implications. The findings from this paper can also be used as policy input in other settings with similar interests in including pharmaceutical treatments for AMD, DME, and RVO.
The country context
Thailand is regarded as one of the countries whose population is aging most rapidly. The proportion of people aged 65 years or older is expected to double over the 20-year period of 2010-2030, with 8.7% of the total population in this category in 2010 compared to a projected 17.4% in 2030. 12 As the population continues to age, visual impairment is expected to rise, leading to a substantial decline in the quality of life among this demographic. AMD, DME, and RVO are among the major causes of irreversible and profound loss of vision in the Thai population. The prevalence of AMD and RVO is currently 0.3% 13 and 0.5%-2% 14 of the total population, respectively. Meanwhile, the prevalence of DME has been reported at about 2%-3% in Thai diabetic patients. 15 Bevacizumab has been licensed in Thailand for the treatment of metastatic cancer of the colon and rectum, while ranibizumab has been approved for the treatment of wet AMD. However, bevacizumab has been widely used off-license in Thailand for the treatment of AMD, DME, and RVO due to its much lower cost (1200 baht/dose) compared to ranibizumab (54,000 baht/dose). Since neither of these drugs is listed in the NLEM, most of the patients treated with bevacizumab or ranibizumab need to shoulder the cost of the treatment by themselves. Furthermore, the recent legal challenge by a pharmaceutical company against local health authorities in England raises serious concern among Thai clinical experts over the use of off-license bevacizumab. [16] [17] [18] Evidence generation A comparative effectiveness study was performed by a research team comprising HITAP researchers and members of the Thai Retina Society, which is a part of the Royal College of Ophthalmologists of Thailand. Detailed information of the methods used for this study is described in Supplementary methods. A systematic review and meta-analysis of relevant randomized controlled trials retrieved from Medline and Scopus up to December 19, 2011 was carried out. Studies assessing the clinical outcomes of bevacizumab, ranibizumab, or nonpharmaceutical interventions for AMD, DME, or RVO patients were eligible for inclusion in the review. The outcomes of interest were central macular thickness (CMT) and visual acuity (VA), which is usually quantified by an Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, logarithm of the minimum angle of resolution (logMAR), or Snellen fraction. An interesting outcome was the number of patients who responded positively to the treatment, which was commonly defined by an improvement in VA equal to or greater than ten or 15 letters of ETDRS or an improvement in VA equal to or greater than two lines of logMAR. A flowchart of the study selection process is presented in Figure S1 , while the basic characteristics of the included studies are shown in Tables S1-S3. Table 1 summarizes the results of the meta-analysis in terms of the treatment effects of bevacizumab, ranibizumab, and nonpharmacological interventions in AMD, DME, and RVO patients. For AMD, four studies [19] [20] [21] [22] reported the treatment response rate of bevacizumab and PDT. Among these four studies, two studies 21, 22 Figure 1A , and Table S4 ). When comparing ranibizumab with bevacizumab in AMD patients, the treatment response rates for these two treatments were not significantly different, with a pooled relative risk (RR) of 0.91 (95% CI 0.71 to 1.16), as shown in Table 1 , Figure 1B and Table S5 . Four studies [23] [24] [25] [26] found that when compared with bevacizumab, ranibizumab could improve VA and decrease CMT in AMD patients. However, these differences did not reach statistical significance.
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Martin et al 25 Overall (I-squared = 0.0%, P = 0.912) Subramanian et al 26 Gharbiya et al 24 Biswas The unstandardized mean differences (USMDs) of VA and CMT between AMD patients receiving ranibizumab compared with bevacizumab were 0.49 ETDRS letters (95% CI -1.37 to 2.34) and -14.18 µm (95% CI -32.06 to 3.70), respectively (see Table 1 , Figure 1C , and Table S6 ).
For DME, three studies [27] [28] [29] showed a significant benefit of bevacizumab over photocoagulation in terms of treatment response rate. As indicated in Table 1 , Figure 2A , and Table S7 , the pooled RR of treatment response rate was 2.40 (95% CI 1.14 to 5.05), which means that DME patients receiving bevacizumab had a 2.4-fold higher chance of responding positively to treatment compared with patients receiving photocoagulation. Four studies 27,29-31 compared bevacizumab and photocoagulation with respect to VA and CMT changes in DME patients. The results from these four studies revealed a significant effect of bevacizumab on improving VA, but failed to show any significant effect of bevacizumab on decreasing CMT when compared with photocoagulation with USMDs of VA and CMT equal to 5.44 ETDRS letters (95% CI 0.05 to 10.83) and 23.61 µm (95% CI -2.78 to 50.00 µm), respectively (see Table 1 , Figure 2B and C, and Table S8 ). Since there was no study that made a Soheilian et al 29 Overall (I-squared = 47.1%, P = 0.129) Solaiman et al 31 Michaelides et al 27 Faghihi et al 30 5 
Mean difference
Bevacizumab vs photocoagulation: USMD of central macular thickness C Figure 2 (A-C) Forest plots of pooled treatment effects of bevacizumab compared with photocoagulation treatment in diabetic macular edema. Abbreviations: RR, relative risk; CI, confidence interval; USMD, unstandardized mean difference; WMD, weighted mean difference.
Overall (I-squared = 0.0%, P = 0.426) Brown et al 47 Kinge et al 32 Campochiaro et al 48 11.39 (9.27, 13.51) direct comparison between bevacizumab and ranibizumab in DME patients, network meta-analysis was then applied for estimating the treatment differences between bevacizumab and ranibizumab. Results from the network meta-analysis show that the treatment effect of ranibizumab was not significantly better than the treatment effect of bevacizumab in terms of VA change, CMT change, and treatment response rate. The pooled RR of response rate and USMD of VA and CMT between ranibizumab and bevacizumab were 1.02 (95% CI 0.52-1.99), 5.12 ETDRS letters (95% CI -17.50 to 27.75), and -51.57 µm (95% CI -169.84 to 66.69), respectively (see Table 1 , and Figures S2-S4 ).
For RVO, only the comparison between ranibizumab and sham according to mean VA change had sufficient data for pooling. Pooling the mean VA changes from three studies 32, 47, 48 revealed the significant benefit of ranibizumab over sham for treating RVO, with a USMD equal to 11.39 ETDRS letters (95% CI 9.27 to 13.51), as seen in Table 1 , Figure 3 , and Table S9 .
For comparison between bevacizumab with sham and bevacizumab with ranibizumab, the results from the network metaanalysis showed no significant difference between these two alternatives in terms of VA change. The USMDs of VA change between bevacizumab with ranibizumab and bevacizumab submit your manuscript | www.dovepress.com Figure S5 .
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Regarding concerns of safety, the analysis examined the adverse events by pooling all data together from three clinical indications. Only the RRs of serious systemic adverse effects (defined as death or serious cardiovascular events such as acute myocardial infarction or stroke) and ocular adverse effects (defined as endophthalmitis, retinal detachment, or vitreous hemorrhage) from all three clinical indications were pooled. Figure S6A illustrates the pooled RR of serious adverse effects from eleven studies [19] [20] [21] [22] [27] [28] [29] [30] [31] 33, 34 that compared the frequency of serious adverse events from bevacizumab and nonpharmacological interventions. The results shown in Figure S6A reveal that there is no clear evidence of the difference in serious systemic and ocular adverse effects among nonpharmaceutical interventions and bevacizumab, with pooled RRs of 1.02 (95% CI 0.39 to 2.65). The results were similar when comparing the risk of serious adverse events resulting from the use of bevacizumab and ranibizumab. The pooled RRs illustrated in Figure S6B produced a result of 1.14 (95% CI 0.52 to 2.51), which means that patients receiving bevacizumab had a nonsignificantly higher risk (14%) of suffering serious adverse events.
Discussion
The findings of this systematic review and meta-analysis indicate that the intravitreal administration of bevacizumab is superior to nonpharmaceutical treatments for AMD and DME but inconclusive for RVO, given the limited evidence. The study also failed to distinguish the differences in terms of VA improvement, reduction of CMT, and response to treatment between AMD and DME patients treated with bevacizumab and those treated with ranibizumab.
In summary, the study confirms the findings from prior systematic reviews on the treatment of AMD and DME, with a caveat being that the study only included results from the largest and latest clinical trials that compared the efficacy of bevacizumab and ranibizumab for AMD. 25, [35] [36] [37] [38] [39] It is also the first study directly to compare clinical outcomes between bevacizumab and ranibizumab, whereas previous studies only assessed the outcomes of bevacizumab or ranibizumab in comparison to nonpharmaceutical interventions.
However, this study does have some limitations. Firstly, a sensible conclusion cannot be reached regarding the safety profiles of these two drugs, since incidences of serious adverse effects are extremely low. The results from the Comparison of Age-Related Macular Degeneration Treatment Trails (CATT) conducted in the US on 1185 AMD patients show similar rates of mortality, myocardial infarction, and strokes for patients receiving either bevacizumab or ranibizumab; however, the proportion of patients with serious adverse effects which resulted in hospitalization was higher among those receiving bevacizumab than those being treated with ranibizumab. 25 The investigators of the CATT study noted that the difference in serious adverse effects may be due to an imbalance in the baseline health status of the sample populations between the case-study and control groups. Secondly, due to the diversity in the reporting of VA using ETDRS, LogMAR, and Snellen fraction, a conversion method developed by Gregori et al 40 to convert all VA outcomes to ETDRS was used. Lastly, this study focused only on clinical outcomes and not on the economic dimension. Raftery et al 41 recently conducted economic modeling to estimate the incremental cost-effectiveness ratio of ranibizumab compared to bevacizumab in the UK. They concluded that ranibizumab will be cost-effective only if it is at least 2.5 times more efficacious than bevacizumab or bevacizumab has more than double the adverse effects of ranibizumab. 41 
Policy implications in Thailand
The preliminary findings of this study were presented on March 28, 2012 in a consultation meeting with stakeholders, including ophthalmologists, academicians, and representatives from the Thai FDA and pharmaceutical industry. Recommendations derived from the meeting include (1) price negotiation with relevant actors within the pharmaceutical industry on ranibizumab; (2) the inclusion of bevacizumab in the NLEM for the treatment of AMD, DME, and RVO if the price negotiation failed to result in equitable prices for both drugs; and (3) the development of a system for monitoring the serious adverse effects of bevacizumab if it is included in the NLEM, as well as to ensure the early withdrawal of the drug if the monitoring system detects any serious problems.
The findings and the above recommendations were reported to the subcommittee on April 24, 2012. After extensive discussion among its members, the subcommittee decided to endorse the use of bevacizumab for the treatment of AMD and DME, but not for RVO. 42 This is due to inadequate evidence to support the use of bevacizumab for RVO. The subcommittee also recommended that all public health plans establish a national registry for health facilities, clinical experts, and patients in order to monitor the drug's safety and effectiveness. It is expected that by 2013, there will be 39,000 AMD patients and 110,250 DME patients receiving bevacizumab treatment.
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This is not the first time that the subcommittee has endorsed the use of off-license medication in the NLEM. Issued in 2009, the most recent such recommendation was to endorse the use of intravenous immunoglobulin for the treatment of myasthenia gravis, acute exacerbation, or myasthenic crisis. 43 The reason for this is that the National Drug Committee allows the NLEM to include off-license medications if there is strong evidence that the safety, efficacy/ effectiveness, and/or efficiency support the use of off-license medications. In this case, these two drugs were developed by the same company -Genentech -although Roche holds the license for bevacizumab and Novartis holds the license for ranibizumab in Thailand. 44 However, there is not enough of an incentive for Roche to license the cheaper drug for the treatment of macular diseases. Although the use of offlicense medication is not legally prohibited in Thailand, clinical experts may feel pressured to use bevacizumab even if it has not been authorized by a national body, given the fact that the more expensive licensed drug is available in the market. This could lead to two negative outcomes for clinical experts, as they may be sued (1) for prescribing a more expensive medication to the patient when it is the patient's right to receive the cheaper treatment to cure the same disease, or (2) for the potential unforeseen incidents off-license medications may cause. Therefore, the inclusion of bevacizumab in the NLEM may elevate such pressure in the short term. The safety profile of bevacizumab for the treatment of macular diseases remains to be seen, and further evaluation is therefore recommended.
To the best of our knowledge, the use of bevacizumab for the treatment of macular diseases remains off-label in all countries including Thailand. Decision-makers and clinicians are facing a very challenging choice of whether to adopt the more expensive ranibizumab, approve the use of off-labeled bevacizumab, or leave this issue to the private market. The last approach may lead to inequitable access to essential treatment for patients with these macular diseases, as most of the patients, especially in developing settings, will not be able to afford ranibizumab and clinicians may be reluctant to prescribe off-label bevacizumab if has not been approved by a national authority. This paper provides information and alternative policy development that will be useful for other settings.
Supplementary materials Search strategy
Medline and Scopus were searched until December 2011 in order to identify relevant studies. The reference lists of previous systematic reviews and included studies were reviewed in order to identify additional eligible studies.
Selection of studies
Two reviewers independently selected the identified studies based on titles and abstracts. Full articles were retrieved if a decision could not be made based on the titles and abstracts alone. Disagreements about selection studies were resolved by consensus with a third party.
Inclusion criteria
Randomized controlled trials were selected if they met all of the following criteria: (1) included at least one of these following study participants -AMD, DME, and RVO; (2) compared any pairs of the following interventions -bevacizumab, ranibizumab, photocoagulation, and sham; (3) measured the outcomes as VA or CMT; (4) allowed the retrieval of full articles and included sufficient data for pooling treatment-effect sizes, such as the number of participants who responded to treatment, mean, and SD of VA and CMT in each treatment group.
Data extraction
Data were extracted independently by two reviewers using standardized data-extraction methods. The author, year of publication, baseline characteristics of participants, number of participants, mean, and SD of the outcomes of interest were extracted. If there were inadequate outcomes in the report, the reviewers contacted the author of each study.
Outcomes
Outcomes of interest were VA, CMT measured in micromillimeters, and numbers of patients who responded to treatment, which was classified in each study. Three methods (ETDRS letter score, logMAR, and Snellen chart score) were used for quantifying VA. However, VA measured by logMar and Snellen chart scores were converted to ETDRS letter scores by using the equation proposed by Gregori et al, as follows. Various criteria were used to classify the definition of response to treatment, with improvement of $15 letters of ETDRS being the most commonly used criterion, followed by improvement of $10 letters of ETDRS and $two lines of logMar.
Statistical analysis
For direct meta-analysis and continuous outcomes, the number of patients, means, and SDs after receiving treatment or mean change (mean after minus before receiving treatment ) in each treatment group of VA and CMT were pooled using USMD. Heterogeneity between studies was assessed using Q and I 2 statistics. If heterogeneity (P-value , 0.1 or I 2 $ 25%) was present, the random-effect model was applied; otherwise, the fixed-effect model was applied. For binary outcomes, the relative risks of response rate from each study were pooled to estimate summary-effect sizes by using the inverse-variance method. However, if heterogeneity was present, the randomeffect model was applied. Sources of heterogeneity were explored by fitting covariables (age, baseline VA and CMT) one by one in metaregression. If sources of heterogeneity were suggested by metaregression, a subgroup analysis according to those covariables was performed.
For indirect comparisons, a network meta-analysis was applied to assess the efficacy of all possible treatment options. For continuous outcomes, a linear regression model weighted with their inverse variances was used to estimate all treatment effects. Effects of the study were fitted as covariables in the model. For binary outcomes, individual patientlevel data were obtained by expanding the summary data using the "expand" command in Stata (StataCorp, College Station, TX). Treatment effects were considered in multilevel data analysis with a log-link function using the "xtpoisson" command. The coefficients of each treatment were used to estimate pooled relative risks and their 95% CIs for each treatment. All analyses were performed using Stata software version 12. A two-sided test with P , 0.05 was considered for statistical significance except for the heterogeneity test, where a one-sided test with P , 0.1 was applied. Figure S1 Flowchart of study selection. Abbreviations: AMD, age-related macular degeneration; DME, diabetic macular edema; RVO, retinal vein occlusion. Relative risk
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Overall (I-squared = 0.0%, P = 0.908) 
